Diving into the Genetics of Target Discovery Using the (Expanded) Open Targets Platform

In 2025, the Open Targets Platform will be updated to include the most comprehensive genetic evidence to date from common and rare genetic variations. This update will include multi-ancestry fine-mapping of publicly available GWAS studies and molecular QTLs resulting in 2.5M credible sets derived from GWAS catalog, eQTL catalogue, Finngen and proteomics from the UK Biobank Pharma Proteomics Project, as well as systematic colocalisation analysis and machine learning-based Locus-2-Gene (L2G) assignment. This webinar will introduce the expanded Platform to the ASHG community, showcasing its new features and how it can drive advances in human genetics research and drug discovery. Participants will gain insights into: 

1. Open Targets Consortium and Open Targets Platform 

2. Open Targets Gentropy 

3. Exploring the updated Platform: Hands-on guidance on navigating the Platform, including features such as variant, study, and credible set pages, which support advanced genetic analysis use cases.